CalciMedica Inc. (NASDAQ:CALC) Stock Has Average Price Target of $50.00

CalciMedica Inc. (NASDAQ:CALC) has earned a consensus recommendation of “Hold” from the five brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $50.00.

A number of research analysts have recently commented on the stock. Weiss Ratings raised shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Wall Street Zen downgraded CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th. UBS Group reissued a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Guggenheim initiated coverage on shares of CalciMedica in a report on Thursday, August 20th. They set a “buy” rating for the company. Finally, HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th.

CalciMedica Stock Up 11.4%

CALC opened at $1.51 on Tuesday. The firm has a 50 day moving average price of $1.60 and a 200 day moving average price of $3.50. CalciMedica has a 1 year low of $1.00 and a 1 year high of $36.00. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58. The company has a market cap of $10.35 million, a PE ratio of -0.22 and a beta of 0.84.

CalciMedica (NASDAQ:CALC) last posted its earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.97. Sell-side analysts expect that CalciMedica will post -5.25 earnings per share for the current year.

Institutional Trading of CalciMedica

An institutional investor recently raised its stake in CalciMedica stock. Renaissance Technologies LLC raised its stake in CalciMedica Inc. (NASDAQ:CALC) by 45.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 128,075 shares of the company’s stock after buying an additional 39,775 shares during the period. Renaissance Technologies LLC owned approximately 0.81% of CalciMedica worth $69,000 as of its most recent filing with the SEC.

CalciMedica Company Profile

CalciMedica, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.